CYP2D6 and neoplasm: The controversy stems from two factors: (1) by relying on tumor samples to derive the CYP2D6 genotype, some studies had genotyping errors and (2) enzymes other than CYP2D6 are involved in the complex metabolism of tamoxifen [36].